Processa R&D chief buys 1,810 PCSA shares
Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share. After this trade, he directly holds 10,562 shares and has additional indirect holdings through the Young-Plaisance Revocable Trust, family entities, and CorLyst, LLC.
Insider Trade Summary
Net Buyer: 1,810 shares
Net Buy
4 txns
Insider
Young David
Role
Pres. Research & Development
Bought
1,810 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,810 | $2.535 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 10,562 shares (Direct);
Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust);
Common Stock — 432 shares (Indirect, By Family Entities);
Common Stock — 742 shares (Indirect, By CorLyst, LLC)
Key Figures
Open-market purchase: 1,810 shares
Purchase price: $2.535 per share
Direct holdings after trade: 10,562 shares
+3 more
6 metrics
Open-market purchase
1,810 shares
Common Stock bought in open market
Purchase price
$2.535 per share
Price for 1,810 Common Stock shares
Direct holdings after trade
10,562 shares
Common Stock held directly post-transaction
Indirect holdings via Young-Plaisance Revocable Trust
1,242 shares
Common Stock held indirectly
Indirect holdings via family entities
432 shares
Common Stock held indirectly
Indirect holdings via CorLyst, LLC
742 shares
Common Stock held indirectly
Key Terms
open-market purchase, indirect ownership, revocable trust, Family Entities, +1 more
5 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
""direct_or_indirect": "I","nature_of_ownership""
revocable trust financial
""nature_of_ownership": "By Young-Plaisance Revocable Trust""
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Family Entities financial
""nature_of_ownership": "By Family Entities""
CorLyst, LLC financial
""nature_of_ownership": "By CorLyst, LLC""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PCSA executive David Young report?
David Young reported an open-market purchase of 1,810 Processa Pharmaceuticals common shares. He paid $2.535 per share, increasing his direct ownership to 10,562 shares while also reporting separate indirect holdings through trusts, family entities, and CorLyst, LLC.
What indirect PCSA holdings are associated with David Young in this Form 4?
The filing shows indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC. These entries reflect ownership through related entities rather than additional open-market purchases.
Was David Young’s PCSA Form 4 transaction a buy or a sell?
The Form 4 reports a buy transaction. David Young completed an open-market purchase of 1,810 Processa Pharmaceuticals common shares, coded as a “P” transaction, with no reported sales or derivative exercises in this filing.
Does this PCSA Form 4 include any derivative securities or option exercises?
This Form 4 does not report any derivative securities or option exercises. The derivative section is empty, and the only reported transaction is an open-market purchase of common stock, plus separate lines showing post-transaction indirect common share holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates